Asia Pacific (APAC) Antirheumatic Drugs market was valued at US$44,513.265 million in 2019. The rapidly growing number of patients suffering from various lifestyle-related diseases is one of the major factors behind the growth of the antirheumatic drug market in the region. There has been a continuous rise in the prevalence of diabetes in countries like China, India, and South Korea. In India, for example, according to the World Bank Group, the prevalence of diabetes among individuals aged between 20 and 79 was 10.39% in 2017. With this increase in diabetic as well as the obese population, the number of people with joint pain is growing tremendously, thus positively impacting the market growth of antirheumatic drugs in this region. Rising out-of-pocket expenditure on healthcare by across this region is leading to a surge in the purchase of generic drugs in the country which is also propelling the overall market for antirheumatic drugs in the Asia Pacific (APAC). The market growth is also being driven by the continuously increasing elderly population in this country.
High investments in R&D across the pharmaceutical industry in this region is also a driving factor for the market growth of antirheumatic drugs in APAC countries. Companies are continuously launching new drugs for various arthritis diseases in this region. For example, in October 2019, Gilead Sciences, Inc. submitted the New Drug Application (NDA) for filgotinib to the Japanese Ministry of Health, Labor, and Welfare (MHLW). This oral, selective JAK1 inhibitor is used for the treatment of adult patients with rheumatoid arthritis (RA). In October 2018, Eli Lily and Company (India) Pvt Ltd launched Olumiant (baricitinib) which is a once-daily oral medication for the treatment of adult patients suffering from moderate-to-severe active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Recent COVID-19 global pandemic outbreak has also impacted the growth of the antirheumatic drug market in this region as governments in APAC countries are using antirheumatic drugs to treat certain symptoms of this virus. For example, in March 2020, China’s National Health Commission approved Roche’s Actemra to treat serious coronavirus patients with lung damage. In India, Bengal’s government has also recommended the use of Tocilizumab, a drug used to treat patients suffering from rheumatoid arthritis, to treat severe COVID-19 cases.
Asia Pacific (APAC) Antirheumatic Drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, Asia Pacific (APAC) Antirheumatic Drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC). By country, the APAC antirheumatic drugs market has been segmented as China, Japan, India, South Korea, Bangladesh, Philippines, Indonesia, Vietnam, Thailand, and Myanmar.